Products
Human alpha1-proteinase inhibitor was approved in many countries in 2016 as a powder and solvent for the preparation of an intravenous infusion solution (Respreeza, USA: Zemaira). It has been approved in the United States since 2003 and in the EU since 2015.
Structure and properties
Human alpha1-proteinase inhibitor is a glycoprotein derived from human plasma. It has not yet been produced recombinantly using biotechnological methods.
Effects
Human alpha1-proteinase inhibitor (ATC B02AB02) is an antagonist of neutrophil elastase (NE) in the lower respiratory tract. Deficiency leads to proteolysis and lung disease. The half-life is 6.8 days.
Indications
As maintenance therapy for adults with severe alpha1-proteinase inhibitor deficiency and clinically manifest lung disease.
Dosage
According to the SmPC. The drug is administered as an intravenous infusion.
Contraindications
- Hypersensitivity
- IgA deficiency and antibodies to IgA
- Decompensated cor pulmonale
For complete precautions, see the drug label.
Adverse effects
The most common possible adverse effects include dizziness and headache. Rarely, hypersensitivity reactions have been reported.
